Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. Read more about Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas.
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. Read more about Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials. Read more about Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials.
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. Read more about Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study.
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. Read more about Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade. Read more about Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade.
Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality. Read more about Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality.
Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review. Read more about Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review.
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review. Read more about Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.
Co-evolution of glioma and immune microenvironment. Read more about Co-evolution of glioma and immune microenvironment.
